Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06138613 · ClinicalTrials.gov registry record · Phase 3
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
A Phase 3 study of Motion Sickness, sponsored by Vanda Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 1
- Study location
NCT06138613 is a Phase 3 study of Motion Sickness that is active but no longer recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 705 participants, above the 38-participant average among 6 other Motion Sickness trials with a reported enrollment target (1755% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06138613, a Phase 3 study of Motion Sickness, is active but no longer recruiting, sponsored by Vanda Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 1
- Study location
Study Summary
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Conditions Studied
Interventions
- DRUG Tradipitant
Study Locations (1)
California
- Santa Monica Clinical Trials - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06138613
The ClinicalTrials.gov registry entry for NCT06138613 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 38-participant average among 6 other Motion Sickness trials with a reported enrollment target (1755% higher). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Motion Sickness appearing as the primary indexed condition, and to 1 intervention - of which Tradipitant is the first listed.
NCT06138613 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06138613 about?
NCT06138613 is a clinical study titled "Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness". An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
What is the current status of trial NCT06138613?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2023-02-27. Estimated completion is 2026-06-30.
What conditions does trial NCT06138613 study?
This clinical trial studies the following conditions: Motion Sickness.
What interventions are being tested in trial NCT06138613?
The interventions under investigation include: Tradipitant (DRUG).
Who is sponsoring clinical trial NCT06138613?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06138613 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
RECRUITING · Phase 2
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Three-Axis Wearable Adaptive Vestibular Stimulator
ACTIVE NOT RECRUITING · NA
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.